Corporate Disclosures

Finance|
|
By Kim Byung-jun
||

▲Hanmi Pharmaceutical (128940.KS) — Signed a technology transfer agreement for sonepeglutide with U.S. pharmaceutical company Eli Lilly, valued at 1.8973 trillion won, with an upfront payment of 112.9 billion won.

▲HD Korea Shipbuilding & Offshore Engineering (009540.KS) — Won an order for eight very large gas carriers (VLGCs) worth 1.4 trillion won.

▲GS E&C (006360.KS) — Selected as the contractor for the Geumjeong District 4 redevelopment project, with an estimated construction value of approximately 338.2 billion won.

▲CI Tech (004920.KS) — Acquiring treasury shares worth 1 billion won to stabilize the share price and enhance shareholder value through cancellation.

▲AEKYUNG Chemical (161000.KS) — Appointed Kim Sung-wan as new CEO, succeeding outgoing CEO Pyo Kyung-won.

▲Daedong Steel (048470.KQ) — Transitioned to a sole CEO structure under Lim Joo-hee following the death of CEO Lim Hyung-ki.

▲BHI (083650.KQ) — Signed a supply contract for LNG combined-cycle power generation equipment, valued at 188.3 billion won.

Companies in this story

Original reporting by Kim Byung-jun for Seoul Economic Daily.

AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.

00:0005:32

AI KEY

Preview
Korean Corporate Intelligence HubKOSPI · KOSDAQ · 12 sectors

A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.

Korea Chaebol Tree

Preview
Families Behind the GroupsKFTC May 2026 · DART filings

An English-first interactive map of Samsung, SK, Hyundai, LG and Lotte — built for foreign investors, correspondents and analysts. Korea translates companies into English. We translate the families behind them.

SIGNAL

Pre-register
English Edition · Capital MarketsM&A · IPO · PE · Fund Flows

Pre-register for SIGNAL English Edition — a premium subscription bringing Korean capital markets coverage (M&A, IPOs, private equity, fund flows) to global institutional investors. First access to the 50% introductory rate.